Scaling up and out: developing a commercial supply chain strategy to successfully deliver next-generation therapiesPublished: February 24, 2020
With the introduction of innovative cell and gene therapies to market, scalable commercial strategies are critical to successfully delivering these therapies to patients. The delivery of cell and gene therapies depends on well-designed supply chains.
Scaling your supply chain up to achieve this requires having, or finding partners with, proven experience in navigating supply chain complexities, coordinating logistics involving multiple stakeholders, and creating customizable solutions to help your company scale efficiently and serve your specific needs from clinical research through to commercial manufacture.
- How to prepare to meet the inevitable increase in supply chain variability through scale-up
- How to allocate sufficient time and resources to mitigate growing supply chain risk as the scale of operations increases
- What proactive preparations and collaborative strategies can be employed to ensure access to the necessary capabilities when you need them
- How to ready your organisation for supply chain success in a highly variable environment where multiple products are in motion at any given time
Tim Tripp, Director of Cell and Gene Therapy Operations, Be The Match BioTherapies®
Tim Tripp is the Director of Cell and Gene Therapy Operations for Be The Match BioTherapies. Tim and his team work closely with clients to understand their unique needs and determine how Be The Match BioTherapies can best support delivery of services based on client specifications.
It is his team’s responsibility to ensure the smooth operational delivery of products and services to clients, such as supply chain management, development and management of collection networks, identifying and sourcing allogeneic donor cells, as well as regulatory compliance.
Tim joined Be The Match BioTherapies’ parent organization, the NMDP/Be the Match, in 2018 as the Director of Specialized Services. Prior to Be The Match, Tim served as Assistant Director of the former Office of University Economic Development (UED) at the University of Minnesota, the Director of the Biotechnology Resource Center (BRC), and the Assistant Director of the Biotechnology Institute (BTI). In the BRC he provided contract biotechnology and fermentation services to industry in partnership with academia. In the BTI he was part of the top administration of a world-class research institute in biotechnology.
Tim was also the Vice President of Corporate Development, Scientist and Program Manager at a start-up vaccine research and development company located in St. Paul, MN. Here, Tim managed a multi-million dollar Department of Defense contract developing biodefense vaccines. In addition, Tim has worked for various private and publicly traded pharmaceutical/medical device manufacturers providing product, and process development for drugs and devices for human use and as a consultant to life science-based industries. Before this, he gained experience in a gram-positive pathogenesis research laboratory where he developed expertise in infectious disease models, molecular biology, and microbiology. He has co-authored multiple peer-reviewed journal articles and presented internationally on various aspects of staphylococcus, streptococcus and enterococcus pathogenesis.
Joy Aho, Senior Product Manager, Be The Match BioTherapies®
Joy Aho, PhD, is the Senior Product Managerat Be The Match BioTherapies®, where she develops innovative products andbest-in-class services for the cell and gene therapy industry. Prior to joiningthe team, she worked in product development and management at Bio-Techne for 13years designing pioneering clinical and discovery tools for the development of celland gene therapies. Aho received her PhD in Molecular, Cellular, andDevelopmental Biology & Genetics from the University of Minnesota, and her researchled her to studying the role of TGFß family proteins during embryonic development utilizingstem cells and developmental models.
Philip Niedzwiedz, Manager & Senior Consultant, Deloitte
Philip is a Manager within the Enterprise Performance portfolio in the Supply Chain and Network Optimization offering. He has been involved in projects related to product development, research optimization, inventory management, commercialization, and navigating FDA regulatory pathways for drug approval. Philip currently focuses on supporting clients in the Next Generation Therapy space, providing expertise for end to end clinical trial operations and logistics solutions. Philip brings experience in vendor due diligence & contracting, process mapping & optimization, and operations integration with manufacturing & QA/QC processes. He specializes in the complex logistics and supply chains often associated with Next Generation Therapies, developing customized solutions to ensure safe and effective patient dosing.